1 1
GSK plc
0 1 2 3 4 5
4.06
2 3
Johnson & Johnson
0 1 2 3 4 5
4.03
3 7
AstraZeneca plc
0 1 2 3 4 5
3.93
4 2
Novartis AG
0 1 2 3 4 5
3.87
5 8
Merck KGaA
0 1 2 3 4 5
3.72
6 4
Pfizer Inc
0 1 2 3 4 5
3.62
7 6
Takeda Pharmaceutical Co, Ltd
0 1 2 3 4 5
3.51
8 5
Sanofi
0 1 2 3 4 5
3.47
9 13
Bayer AG
0 1 2 3 4 5
3.36
10 9
Roche Holding AG
0 1 2 3 4 5
3.23
11 10
Novo Nordisk A/S
0 1 2 3 4 5
2.97
12 11
Eisai Co, Ltd
0 1 2 3 4 5
2.95
13 12
Boehringer Ingelheim
0 1 2 3 4 5
2.93
14 14
Gilead Sciences
0 1 2 3 4 5
2.84
15 19
Bristol Myers Squibb
0 1 2 3 4 5
2.60
16 14
Astellas Pharma Inc
0 1 2 3 4 5
2.46
17 16
Daiichi Sankyo Co, Ltd
0 1 2 3 4 5
2.20
18 15
Merck & Co, Inc
0 1 2 3 4 5
2.15
19 17
AbbVie Inc
0 1 2 3 4 5
1.84
20 18
Eli Lilly & Co
0 1 2 3 4 5
1.79
0 1 2 3 4 5

In the 2021 Index, dense ranking was used. In the 2022 Index, standard competitive ranking is used. Therefore, a direct comparison with the previous ranks of AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Merck & Co, Inc (MSD) is not possible.

The ranking above shows the position and score of each company in the 2022 Index (left) and 2021 Index (right). Click on a company's name to go to its full report card.

2021 Benchmark

Pharma companies press on in fight against drug resistance, yet lag in access to antibiotics.

The 2021 AMR Benchmark evaluates 17 companies with a major stake in the anti-infectives space, including large research-based companies and generic medicine manufacturers. By comparing how they perform across a set of 20 metrics, the Benchmark tracks the progress and gaps in their efforts to keep medicines and vaccines available, despite the rise of drug resistance.

Large R&D-based companies

84%
GSK
Projects in the pipeline: 31
Products on the market: 51
Score breakdown
Research & Development: 93%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
81%
Pfizer
Projects in the pipeline: 13
Products on the market: 116
Score breakdown
Research & Development: 77%
Responsible Manufacturing: 80%
Appropriate Access: 80%
Stewardship: 90%
68%
Johnson & Johnson
Projects in the pipeline: 14
Products on the market: 8
Score breakdown
Research & Development: 50%
Responsible Manufacturing: 80%
Appropriate Access: 72%
Stewardship: 80%
63%
Novartis
Projects in the pipeline: 0
Products on the market: 109
Score breakdown
Research & Development: 7%
Responsible Manufacturing: 87%
Appropriate Access: 80%
Stewardship: 75%
60%
Sanofi
Projects in the pipeline: 6
Products on the market: 47
Score breakdown
Research & Development: 33%
Responsible Manufacturing: 73%
Appropriate Access: 84%
Stewardship: 60%
58%
Shionogi
Projects in the pipeline: 11
Products on the market: 8
Score breakdown
Research & Development: 70%
Responsible Manufacturing: 93%
Appropriate Access: 4%
Stewardship: 80%
57%
Otsuka
Projects in the pipeline: 4
Products on the market: 1
Score breakdown
Research & Development: 56%
Responsible Manufacturing: 43%
Appropriate Access: 60%
Stewardship: 65%
46%
MSD
Projects in the pipeline: 13
Products on the market: 19
Score breakdown
Research & Development: 47%
Responsible Manufacturing: 73%
Appropriate Access: 29%
Stewardship: 55%

Generic medicine manufacturers

71%
Aurobindo
Projects in the pipeline: 0
Products on the market: 39
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 60%
Stewardship: 87%
69%
Abbott
Projects in the pipeline: 0
Products on the market: 85
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 53%
Stewardship: 80%
67%
Viatris
Projects in the pipeline: 0
Products on the market: 87
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 73%
Appropriate Access: 72%
Stewardship: 53%
63%
Fresenius Kabi
Projects in the pipeline: 0
Products on the market: 51
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 53%
Stewardship: 80%
60%
Cipla
Projects in the pipeline: 0
Products on the market: 59
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 67%
Appropriate Access: 40%
Stewardship: 87%
60%
Teva
Projects in the pipeline: 0
Products on the market: 137
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 60%
Appropriate Access: 47%
Stewardship: 80%
47%
Sun Pharma
Projects in the pipeline: 0
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 47%
Stewardship: 60%
20%
Alkem
Projects in the pipeline: 0
Products on the market: 52
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 33%
Appropriate Access: 20%
Stewardship: N/A
15%
Hainan Hailing
Projects in the pipeline: 0
Products on the market: 43
Score breakdown
Research & Development: N/A
Responsible Manufacturing: 20%
Appropriate Access: 20%
Stewardship: N/A
Room to improve Performance so far